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A Variant in MCF2L Is Associated with Osteoarthritis
Aaron G. Day-Williams,1 Lorraine Southam,1,2 Kalliope Panoutsopoulou,1 Nigel W. Rayner,2
Tonu Esko,3,4,5 Karol Estrada,6,7 Hafdis T. Helgadottir,8 Albert Hofman,9 Throvaldur Ingvarsson,10,11
Helgi Jonsson,11,12 Aime Keis,13,14 Hanneke J.M. Kerkhof,6,7 Gudmar Thorleifsson,8 Nigel K. Arden,15,16
Andrew Carr,17 Kay Chapman,17 Panos Deloukas,1 John Loughlin,18 Andrew McCaskie,18,19
William E.R. Ollier,20 Stuart H. Ralston,21 Timothy D. Spector,22 Gillian A. Wallis,23
J. Mark Wilkinson,24,25 Nadim Aslam,26 Fraser Birell,18,27 Ian Carluke,27 John Joseph,28 Ashok Rai,29
Mike Reed,27 Kirsten Walker,27 arcOGEN Consortium, Sally A. Doherty,30 Ingileif Jonsdottir,8,11
Rose A. Maciewicz,31 Kenneth R. Muir,32 Andres Metspalu,3,4,5 Fernando Rivadeneira,6,7,9
Kari Stefansson,8,11 Unnur Styrkarsdottir,8 Andre G. Uitterlinden,6,7,9 Joyce B.J. van Meurs,6,7
Weiya Zhang,30 Ana M. Valdes,22 Michael Doherty,30 and Eleftheria Zeggini1,*
Osteoarthritis (OA) is a prevalent, heritable degenerative joint disease with a substantial public health impact.We used a 1000-Genomes-
Project-based imputation in a genome-wide association scan for osteoarthritis (3177 OA cases and 4894 controls) to detect a previously
unidentified risk locus. We discovered a small disease-associated set of variants on chromosome 13. Through large-scale replication, we
establish a robust association with SNPs in MCF2L (rs11842874, combined odds ratio [95% confidence interval] 1.17 [1.11–1.23],
p¼ 2.13 108) across a total of 19,041 OA cases and 24,504 controls of European descent. This risk locus represents the third established
signal for OA overall.MCF2L regulates a nerve growth factor (NGF), and treatment with a humanizedmonoclonal antibody against NGF
is associated with reduction in pain and improvement in function for knee OA patients.
Osteoarthritis (OA) is the most common form of arthritis
and is associated with a large health economic burden.1
The sibling recurrence risk (ls) for OA has been estimated
to be approximately 5 in the UK.1 Two loci (GDF5 [MIM
601146] on chromosome 20 and a signal on chromosomal
region 7q22, both with allelic odds ratios of ~1.15) have
reached genome-wide significance in European popula-
tions.2–5 This paucity of established risk loci could be
ascribed to limitations caused by insufficient sample sizes,
phenotype heterogeneity, resolution of known variation,
associations with low-frequency and/or rare variants,
interaction effects, or structural variation.6,7 We recently
carried out a large genome-wide association scan (GWAS)
restricted to knee and/or hip OA and detected no repli-
cating signals (arcOGEN GWAS).8 Imputation based on
the 1000 Genomes Project (1KGP) has been proposed as
an approach that will increase power and resolution in
genetic association studies,9 and researchers have already
applied the technique to fine map known association
signals.10,11 In this work, we applied a 1KGP-based imputa-
tion and identify a genome-wide significant locus for OA
within a gene previously unlinked to the disease.
We used 1KGP pilot 1 data of 60 CEU individuals as
a reference set and imputed 1KGP-identified variants
into the arcOGEN GWAS of 3177 cases and 4894 UK con-
trols12–14 (Figure 1). The set of 3177 OA cases are unrelated
individuals of European ancestry collected in the UK on
the basis of two criteria: (1) radiographic evidence of
disease (defined as a Kellgren-Lawrence [KL] grade R 215)
and/or (2) clinical evidence of disease requiring joint
replacement (TJR). The 4894 UK-population-based con-
trols were unrelated individuals from the 1958 British
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IS-101, Iceland; 9Department of Epidemiology, Erasmus Medical Center, Rotterdam 3000 CA, The Netherlands; 10University of Akureyri, Department of
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Birth Cohort (58BC) and the UK National Blood Donor
Service (UKBS) and were obtained from an early release
of the Wellcome Trust Case Control Consortium 2
(WTCCC2) data. The genotyping and quality control
(QC) of these individuals and their genotype data were
described previously in the initial arcOGEN GWAS.8 Our
primary 1KGP imputation was based on the April 2009
release of haplotypes for 57 individuals. After removing
rare variants (with minor allele frequency [MAF] < 0.01)
and SNPs with low imputation quality (r2 < 0.3),
7,258,070 variants were tested for association with OA.
Further quality control was applied by closely examining
all SNPs with p < 105 in the association test, removing
poorly clustering directly-typed SNPs in their vicinity
(up to 300 kb away), and repeating the imputation step
with the August 2009 1KGP release of haplotypes from
56 individuals and reassessing evidence for association.
We selected eight SNPs from six loci for validation in the
original arcOGEN data and for de novo genotyping in
independent follow-up sample sets (Table S1, available
online).
As part of our follow-up, we first genotyped an indepen-
dent set of 5165 arcOGEN-collected cases and 6155 popu-
lation-based controls from the 58BC and UKBS cohorts.
Seven out of the eight SNPs were successfully typed with
a Sequenom MassArray iPLEX Gold assay (Table S1) and
one SNP, rs11842874 on 13q34, replicated with p ¼
2.60 3 103 (allelic odds ratio [OR] 1.17 [1.06–1.30])
and with consistent effect direction as the original scan
(Figure 2, Table 1). We subsequently took this signal
forward to de novo genotyping in two further sample
sets from the UK: the Genetics of Osteoarthritis and Life-
style (GOAL) study16,17 (1686 total joint replacement
cases, 743 non-OA controls) and an additional indepen-
dent set of 2409 newly recruited arcOGEN cases and
2319 population-based controls from the 58BC and
UKBS cohorts. The combined UK meta-analysis (n ¼
12,437 cases, 14,111 controls) allelic OR was 1.22 [1.14–
1.30], p ¼ 2.24 3 108. We further investigated associa-
tion with this variant in four non-UK OA sample sets:
two from the Netherlands (Rotterdam Study I [RSI], 1950
cases and 3243 controls, and Rotterdam Study II [RSII],
485 cases and 1460 controls, both in silico),18–20 one
sample set from Estonia (Estonian Genome Center,
University of Tartu [EGCUT], 2617 cases and 2619
controls, de novo genotyping),21,22 and one from Iceland
(deCODE, 1552 cases and 3071 controls, de novo geno-
typing). We used a meta-analysis framework to combine
results across the follow-up studies only and across all
data. We obtained the combined estimates of ORs for
reference alleles by weighting the logORs of each study
by the inverse of their variance via a fixed effects model.
We investigated evidence of heterogeneity of ORs by using
the Cochran’s Q and I2 statistics. The meta-analysis was
performed with the GWAMA software package.23 In all
seven follow-up datasets combined, rs11842874 was asso-
ciated with OA with p ¼ 3.0 3 105 (allelic OR 1.13 [1.07–
1.20]). Combined with the discovery sample set, the over-
all fixed effects meta-analysis (across 19,041 cases and
24,504 controls) established association at this variant
with p ¼ 2.073 108 (allelic OR 1.17 [1.11–1.23]; Figure 2,
Table 1). The variant appears to be more strongly associ-
ated with knee OA (allelic OR 1.17 [1.10–1.25], p ¼
2.52 3 106, effective sample size of 28,987) than with
hip OA (allelic OR 1.11 [1.03–1.19], p ¼ 3.54 3 103,
effective sample size of 27,452). Studies contributing
data to this manuscript acquired informed consent from
all participants and were approved by the appropriate
ethics committee(s) for the respective institutions and
countries.
rs11842874 is one of several highly correlated SNPs at
13q34 and constitutes the observed association signal,
which spans 12.7 kb (Figure 3). The surrounding 1 Mb
region is characterized by low levels of linkage disequilib-
rium and contains only nine SNPs correlated with
rs11842874 at r2 > 0.7. rs11842874 was selected for repli-
cation because it is the only variant present on some
GWAS platforms. The OA risk-increasing allele is the major
allele with population frequency of 0.927 (mean over the
UK control data), and as a common variant with low OR,
it contributes little to the sibling recurrence risk (estimated
ls ¼ 1.001). All SNPs that comprise the signal reside in
intron 4 of MCF2L (MCF.2 cell-line-derived transforming
sequence-like [MIM 609499], encoding the guanine nucle-
otide exchange factor). Mcf2l studies in rat models of OA
have shown expression in articular chondrocytes.24,25 In
Impute on the basis of 1000 Genomes Project pilot 1 data
Test for associaon in 3,177 cases 
and 4,894 UK controls across ~7.2M variants with MAF>0.01
Closely examine signals with p<10-5 and remove low quality variants
Reimpute and retest for associaon
Replicate 6 promising signals in 5,165 cases and 6,155 UK controls
Replicate chr13 signal in 4 further European populaons 
of 6,604 cases and 10,393 controls
Validate 6 promising  imputed signals in the original GWAS samples
Replicate chr13 signal in 2 further sets of 4,095 cases and 3,062 UK controls 
Figure 1. Overview of Study Design
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human cells MCF2L regulates neurotrophin-3-induced
cell migration in Schwann cells.26 Neurotrophin-3 is a
member of thenerve growth factor (NGF) family. Treatment
of knee OA patients with a humanized monoclonal anti-
body that inhibits NGF was found to be associated with
joint pain reduction and an improvement in func-
tion.27,28
The MCF2L OA locus was taken forward on the basis of
evidence accrued through 1KGP-based imputation. Direct
typing of ~600,000 SNPs through GWAS resulted in
modest (p > 105) evidence for the association of a single
variant, rs11842874, with OA in this region and
HapMap-based imputation left the picture unchanged
(Figures 3A and 3B). Prioritization strategies for follow-up
in our published GWAS8 down-weighted lone variants
with no corroboration of association from neighboring
SNPs. The denser 1KGP reference set empowered the asso-
ciation of multiple additional correlated (i.e., noninde-
pendent), imputed variants, several of which showed
stronger evidence for association with OA, thus high-
lighting this region for validation and replication geno-
typing (Figure 3C, Table S1).
The associated variants are common, but their minor
allele frequencies are toward the lower end of the fre-
quency spectrum (at ~0.07). The identification of similar
variants withmodest effect sizes (OR 1.17) at genome-wide
significance levels will require sample sizes in the order of
~23,000 cases and an equal number of controls. Through
several rounds of cluster-plot inspection, removal of poor
quality SNPs, and reimputation, we observed that the
Figure 2. Forest Plot of OA Association and Meta-Analysis Results for rs11842874
The purple squares designate the estimated Odds Ratio (OR) for each individual study and the error bars extending out on both sides
show the 95% confidence interval for the OR estimate. The pink diamond designates the estimated OR of the fixed effects meta-analysis
of all the studies.
Table 1. OA Association and Meta-Analysis Results for rs11842874
Study Number Cases Number Controls Effect Allele MAF OR (95% Confidence Interval) p value
arcOGEN GWAS 3177 4894 A 0.0718 1.32 (1.16–1.50) 1.67 3 105
arcOGEN replication set 1 5165 6155 A 0.0694 1.17 (1.06–1.30) 2.60 3 103
GOAL 1686 743 A 0.0720 1.23 (0.99–1.56) 7.20 3 102
arcOGEN replication set 2 2409 2319 A 0.0636 1.16 (0.98–1.37) 7.86 3 102
UK meta-analysis 12437 14111 A 1.22 (1.14–1.30) 2.24 3 108
deCODE 1552 3071 A 0.0917 1.03 (0.88–1.20) 7.31 3 101
EGCUT 2617 2619 A 0.0769 1.16 (1.01–1.34) 4.01 3 102
RSI 1950 3243 G 0.0608 1.01 (0.86–1.20) 8.61 3 101
RSII 485 1460 A 0.0715 1.46 (1.07–2.00) 1.68 3 102
Non-UK meta-analysis 6604 10393 A 1.09 (1.00–1.19) 4.70 3 102
Combined meta-analysis 19041 24504 A 1.17 (1.11–1.23) 2.07 3 108
Meta-analysis results are denoted in bold.
448 The American Journal of Human Genetics 89, 446–450, September 9, 2011
majority of signals were caused by genotyping and imputa-
tion artifacts. This fact highlights the need for imputed
signals to be scrutinized postimputation before follow-up
studies are deployed. As the field of complex trait asso-
ciation studies shifts its focus toward low-frequency
and rare variants, thorough quality control of signals
becomes highly relevant. In this study, we have restricted
1KGP-based imputation to variants with an MAF > 0.01.
As reference panel sizes become larger, imputation of lower
frequency variants will becomemore feasible, empowering
Figure 3. Comparison of Regional Association
Plots at the Chromosome 13 Association Signal
Evidence for association in the rs11842874
region for (A) arcOGEN GWAS directly typed
analysis,8 (B) arcOGEN HapMap3 imputation
analysis, and (C) arcOGEN 1KGP final pilot 1
release imputation analysis. The x axis shows
the build 36 chromosome 13 base position 5
500 kb of rs11842874. The left y axis is the
log (p value) of SNPs in the region, and the right
y axis is the recombination rate (cM/Mb) as calcu-
lated from the pilot 1 release of the 1KGP. Each
diamond represents a variant and is colored ac-
cording to its correlation (r2) with rs11842874.
The green arrows below provide an overview of
the genes in the region and their transcriptional
direction. Imputed variants are denoted by circles
and directly typed variants are denoted by dia-
monds.
the examination of rare variation in next
generation association studies.
The genetic architecture of OA has not
been elucidated yet. By identifying this
susceptibility locus, the third one discov-
ered for OA, our study now provides a foun-
dation on which functional studies can
be based. New additions to the genetic
study toolset, including larger sample sets,
well-characterized phenotypes, and rese-
quenced reference-panel-based imputation
approaches hold the promise of providing
insights into the etiology of this common
degenerative joint disease.
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